Cargando...
Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2
The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibi...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3732786/ https://ncbi.nlm.nih.gov/pubmed/23153531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.10.016 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|